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Summary Sex hormone binding globulin (SHBG) concentrations were measured by immunoradiometric
assay in serum samples from 1,221 healthy female volunteers aged 34-79 who had never used oral
contraceptives or hormone replacement therapy, had no history of thyroid disease or cancer, and had not
used any drugs known to influence SHBG in the 14 days preceding blood sampling. There were 616
premenopausal and 605 naturally postmenopausal women. In both premenopausal and postmenopausal
women, SHBG decreased with increasing weight (Quetelet's Index) and was lower in single nulliparous
women than in married nulliparous women or parous women. In premenopausal women, SHBG was higher
in women with late menarche, was higher in smokers than in non-smokers, and was higher in blood samples
taken during the first 12 days of the luteal phase than during the rest of the menstrual cycle. In
postmenopausal women, SHBG increased with years since the menopause. The possible biological importance
of these findings is discussed with particular reference to risk factors for breast cancer.
There is evidence that the risk of developing breast cancer is
enhanced by increased exposure of breast epithelial cells to
oestradiol (E2) (Henderson et al., 1982). The amount of E2
which reaches breast cells is determined by the concentration
of E2 in the plasma and by the proportion of this E2 which
is able to leave the plasma and enter the cells. About 98% of
plasma E2 is bound either to albumin or to sex hormone
binding globulin (SHBG). Anderson (1974) argued that only
the small percentage of E2 which is not bound to albumin or
to SHBG (i.e. the free E2 fraction) is able to cross cell
membranes, but there is some evidence that E2 bound to
albumin may also be biologically active (Pardridge, 1981).
SHBG concentration is a major determinant of the
proportions of E2 bound to SHBG, bound to albumin, and
free (Siiteri et al., 1981). Severaf studies have included
measurements of E2 binding and of the concentration (or
binding capacity) of SHBG in breast cancer cases and
controls. In most of these studies, and in one prospective
study, women with breast cancer and women who were later
diagnosed with the disease were found to have a higher
percentage of free E2 than controls. This difference was
often accompanied by a low SHBG concentration or SHBG
binding capacity, and by an increase in the percentage of
albumin bound E2 (see Moore et al., 1986).
The mechanism of action of most of the known breast
cancer risk factors (in particular, the reproductive and
menstrual risk factors) is poorly understood. Bernstein et al.
(1985) reported that SHBG binding capacity is higher in
parous than in nulliparous women, and suggested that this
difference in SHBG might be one mechanism by which
parity reduces the risk of breast cancer. It is possible that
other risk factors for breast cancer may also modify risk
because they are related to SHBG. To investigate this we
have measured the SHBG concentration in serum samples
from almost 5,000 women living on the island of Guernsey.
This report presents our findings on the epidemiology of
SHBG in a subset of 1,221 women who had never used oral
contraceptives or hormone replacement therapy, and had
never had thyroid or other endocrine diseases. Details of
drug use during the 14 days prior to blood collection were
recorded, and subjects who had used drugs likely to affect
SHBG were excluded. An analysis of the effects of current
Correspondence: T.J.A. Key.
Received 9 April 1987; and in revised form, 1 August 1987.
and past use of oral contraceptives and hormone
replacement therapy on SHBG in this population will be the
subject of another publication.
Subjects and methods
Subjects
Between 1978 and 1984, blood samples were taken from
approximately 5,000 women aged 34 years and above who
volunteered for mammographic screening. Premenopausal
women were asked to attend for blood collection irrespective
of the stage of their menstrual cycle. Serum was stored at
-20°C in 2ml amounts. Height and weight were measured
and a questionnaire was completed giving details of
reproductive history, menopausal status, and day of
menstrual cycle, as well as information on previous diseases,
use of oral contraceptives and hormone replacement therapy,
and use of other drugs within the 14 days preceding blood
sampling. A woman was defined as premenopausal if she
had menstruated in her usual pattern during the previous six
months, perimenopausal if she had menstruated at least once
during the previous six months but her pattern of
menstruation had become less regular than usual, and
postmenopausal if she had not menstruated for 6 months or
more. Postmenopausal women were classified as artificially
postmenopausal if they had had a hysterectomy before their
periods had ceased for 6 months or if they had undergone a
bilateral ovariectomy at any time.
SHBG concentration was measured in serum samples from
4,913 women. Subjects were then excluded from the current
analysis if they met any of the following criteria: height
unknown, weight greater than 100kg, age at menarche
unknown, age greater than 79 years, history (or possible
history) of thyroid disease, previous breast or other cancer,
ever use of exogenous sex hormones, menopausal status
other than premenopausal or naturally postmenopausal, day
of menstrual cycle on which blood sample taken unknown,
age at menopause unknown, use during the 14 days before
blood sampling of drugs which might affect SHBG
(barbiturates, phenytoin, corticosteroids, drugs for thyroid
disease and for diabetes; see Lindstedt et al., 1985). These
exclusions left us with data on 1,221 subjects, 616 of whom
were premenopausal and 605 naturally postmenopausal.
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Assay
SHBG concentration was measured by a liquid phase
immunoradiometric assay (IRMA) (Hammond et al., 1985)
using antisera kindly supplied by Dr G.L. Hammond,
University of Western Ontario, London, Ontario, Canada.
All serum samples were assayed between June 1984 and June
1986. Very few of the samples had been thawed and re-
frozen before the SHBG assay. In order to minimise biases
introduced by inter-assay variation and by different storage
times, each assay batch of - 90 samples included groups
which had been collected at different times between 1978 and
1984. A single measurement was made on each sample, but
every assay batch included a number of quality control
samples. These usually comprised 1 set of 10 or 2 sets of 5
samples from serum pools with different SHBG
concentrations in the range 26.0 to 112.0nmol -1. The inter-
assay coefficients of variation for the square root of SHBG
(see below) at these different concentrations ranged from
1.6% to 6.0%. The intra-assay coefficients ofvariation ranged
from 2.6% to 4.7%.
Examination of the assay results suggested that SHBG
concentrations tended to be higher in the samples which had
been stored longer. Assay dates had not been entered on the
computer, therefore we assessed the approximate storage
time by using the serial number of the samples (these were
allocated consecutively during sample collection): because the
duration of sample collection (1978-1984) was much longer
than the period during which the samples were assayed
(1984-1986), the error introduced by this approximation is
small. There was an approximately linear inverse correlation
between serial number and SHBG concentration (r=0.11,
P<0.001). The unselected recruitment of subjects should
minimise the bias introduced by this relationship: to further
reduce bias, serial number was used as a covariate in all
further statistical procedures (see below).
Statistical analysis
Simple regression and the analysis of covariance were used
to examine the relationship between serum SHBG
concentration and variables of interest recorded on the
questionnaires. The SPSS-X package (SPSS Inc., 1986) was
used for all calculations. One-sided tests of significance were
used. The significance levels quoted can be converted to two-
sided values by multiplying the one-sided value by 2.
Before making any statistical computations we examined
the distributions of SHBG concentration, of the logarithm of
SHBG, and of the square root of SHBG. The distribution of
the square root of SHBG was closest to normal. We
therefore used the square root of SHBG in all further
computations, but the values shown in the tables and figures
have been returned to their original units by squaring the
computed mean values.
Univariate correlation coefficients were computed between
SHBG concentration and four indices of body size: weight,
log weight, weight divided by height, and Quetelet's Index
(weight divided by the square of height). All four indices
examined had very similar correlations with SHBG. We
chose to use Quetelet's Index (QI) as the index of body size
in our analysis because it is the most widely used and
understood unit. The correlation coefficients between SHBG
and QI were -0.29 in premenopausal and -0.35 in
postmenopausal women, both P<0.001. QI was used as a
covariate in all analyses of the relationship between SHBG
and other variables.
Detailed analysis (see below) showed that, in addition to
serial number and QI, several other variables were related to
SHBG. These variables were: parity (0, 1+) and marital
status (single, ever married) in both premenopausal and
postmenopausal women, day of cycle of blood sample and
age at menarche in premenopausal women only, and the
number of years since menopause in postmenopausal
women. In the tables which follow, the SHBG values are
shown before and after adjustment for these variables. The
values shown in Figures 1, 2, 4 and 5 are all adjusted for
these variables. All the values shown in the tables and figures
have been corrected for serial number: this correction
produced only small changes in the values.
Results
SHBG and time ofday at which blood was taken
There was no difference between the mean SHBG
concentration of samples taken at different times of day
between 10.00 and 20.00h.
SHBG and QI
Figure 1 shows the relationship between SHBG concen-
tration and QI. There is a marked and highly statistically
significant inverse relationship between SHBG and QI in
both premenopausal (test for trend adjusting for day of
cycle, age at menarche, parity (0, 1+), marital status and
serial number: P<0.001) and postmenopausal (test for trend
adjusting for parity (0, 1+), marital status, years since
menopause and serial number: P<0.001) women. In pre-
menopausal women there is little decrease in SHBG until
QIs of 26+ kgm 2. In both premenopausal and post-
menopausal women, the average serum SHBG concen-
tration of women with QIs of less than 20kgm 2 is almost
twice that of women with QIs of 32kgm-2 and above.
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Figure 1 Relationship between SHBG and QI. Premenopausal
P<0.001. Postmenopausal P<0.001.
SHBG and menopausal status
After adjustment for QI and correction for serial number,
the mean SHBG was 67.2nmol1-1 in premenopausal women
and 60.1 nmol1-1 in postmenopausal women, This difference
is highly statistically significant (P<0.001). In the rest of the
analysis premenopausal and postmenopausal women are
therefore considered separately.
SHBG, parity and marital status
Table I shows the relationships between SHBG, parity, and
marital status. Table I(A) shows SHBG in subjects classified
as either nulliparous or parous. In premenopausal women
the nulliparous subjects have a lower mean SHBG than the
parous subjects, (adjusting for QI, day of cycle, age at
menarche and serial number: P=0.004) but,there is no such
difference in postmenopausal subjects. Table I(B) shows that,
among parous subjects, there is no relationship between
SHBG and number of births. Table I(C) shows SHBG in
nulliparous subjects subdivided according to marital status. |E|s|s~~~~~~~~~~~~~~~~
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Table I(A) Relationship between SHBG and parity: Nulliparous
versus parousa
Premenopausal Postmenopausal
SHBG SHBG
Parity Unadj.b Adj.c N Unadl.b Adj.d N
0 63.4 62.4 93 62.6 59.6 119
1 + 69.7 69.9 523 57.8 58.5 486
Total 68.7 68.7 616 58.7 58.7 605
Table I(B) Relationship between SHBG and parity in parous
women
Premenopausal Postmenopausal
SHBG SHBG
Parity Unadj.b Adj.c N Unadj.b Adj.d N
1 68.1 69.2 75 59.6 58.4 110
2 70.4 70.2 245 57.6 56.4 167
3 68.6 67.4 127 57.3 58.4 104
4 72.3 73.8 59 55.4 55.2 56
5+ 68.6 68.2 17 58.1 62.9 49
Total 69.7 69.7 523 57.8 57.8 486
Table I(C) Relationship between SHBG and marital status in
nulliparous women
Premenopausal Postmenopausal
SHBG SHBG
Marital
status Unadj.b Adj.c N Unadj.b Adj.d N
Single 56.7 58.2 41 57.8 52.6 36
Ever-married 68.9 67.6 52 65.0 67.4 83
Total 63.4 63.4 93 62.6 62.6 119
aAbbreviations: N =number of subjects; QI =Quetelet's Index;
SHBG= sex hormone binding globulin; Unadj.=unadjusted. bMean
value (nmolI-1), corrected for serial number. cAdjusted for QI, day
of cycle and age at menarche, and corrected for serial number.
dAdjusted for QI and years since menopause, and corrected for serial
number.
In both premenopausal and postmenopausal women SHBG
is lower in single nulliparous women than in ever-married
nulliparous women (premenopausal, adjusting for QI, day of
cycle, age at menarche and serial number: P=0.047;
postmenopausal adjusting for QI, years since menopause and
serial number: P=0.001).
SHBG and age at menarche
Figure 2 shows the relationship between SHBG and age at
menarche when the data are not adjusted for QI. In
premenopausal women there is a highly significant positive
relationship between SHBG and age at menarche (test for
trend adjusting for parity (0, 1+), marital status, day of
cycle and serial number: P=0.005). The crude relationship
was little affected by adjusting for parity, marital status and
day of cycle, but was reduced in magnitude by adjusting for
QI (test for trend adjusting for QI, parity (0, 1+), marital
status, day of cycle and serial number: P=0.058), because
there is a marked inverse relationship between QI and age at
menarche (Figure 3). In postmenopausal women the
unadjusted values showed a tendency for SHBG to be higher in
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Figure 2 Relationship between SHBG and age at menarche.
Premenopausal P=0.058. Postmenopausal P>0.1.
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Figure 3 Relationship between QI and age at menarche.
Premenopausal P<0.001. Postmenopausal P=0.007.
women who had a late menarche (Figure 2), but no
relationship between SHBG and age at menarche remains
after adjustment for QI because postmenopausal women also
show a marked inverse relationship between QI and age at
menarche (Figure 3).
SHBG and years since menopause
Figure 4 shows that there is an approximately linear
relationship between SHBG and number of years since the
menopause in postmenopausal women (test for trend using
number of years since last menstrual period and adjusting
for QI, parity (0, 1+), marital status and serial number:
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Figure 4 Relationship between SHBG and number of years
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P=0.012). This relationship was not changed by adjusting
for age or age at menopause, which both showed similar but
weaker relationships with SHBG in postmenopausal women
which were not significant after adjusting for years since
menopause.
SHBG and day ofmenstrual cycle
Figure 5 shows SHBG plotted against the number of days
before the end of the cycle; day 0 is the day on which
subsequent menstruation begins, days 1 to 14 are the 'luteal
phase', and days 15+ are the 'follicular phase' of an
'average' ovulatory cycle. SHBG is higher in samples taken
during the first 12 days of the luteal phase than in the
follicular phase, but falls in the last 2 days of the cycle. In
order to adjust for day of cycle in the other statistical
analyses, we classified subjects into the 3 cycle phases shown
in Table II: days 0 to 2 are the last 2 days of the cycle and
the day on which subsequent menstruation began, days 3 to
14 are the first 12 days of the luteal phase (assuming an
'average' 14 day luteal phase), and days 15+ are the
follicular phase. Table II shows that SHBG is about 9%
higher in the first 12 days of the luteal phase than in the
follicular phase, but drops by about 14% at the end of the
luteal phase (test between 3 groups, adjusting for QI, parity
(0, 1+), marital status, age at menarche and serial number:
P=0.002). After adjusting for stage of cycle, we found no
relationship between SHBG and the length of the cycle in
which the blood was taken.
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Figure 5 Relationship between SHBG and day of cycle on
which blood was taken in premenopausal women.
Table II Relationship between SHBG and the day
of the menstrual cycle on which blood was taken in
premenopausal womena
Number ofdays SHBG
before the end
ofthe cycle Unadj.b Adj.c N
0-2 'premenstrual' 62.3 62.4 76
3-14 'luteal' 72.3 72.6 256
15+ 'follicular' 67.4 66.9 284
Total 68.7 68.7 616
aAbbreviations: N=number of subjects; QI =
Quetelet's Index; SHBG =sex hormone binding
globulin. bMean value (nmol -l), corrected for
serial number. cAdjusted for QI, parity (0,1+),
marital status, and age at menarche, and corrected
for serial number.
SHBG andsmoking
Information on smoking habits was only collected for about
28% of subjects. Table III shows that in premenopausal
women, SHBG concentration is 14% higher in smokers
than in non-smokers (adjusting for QI, day of cycle, parity
(0, 1+), marital status, age at menarche and serial number:
P=0.051). In postmenopausal women, smokers again have
higher SHBG concentrations but the unadjusted mean
difference of 8% was reduced to 5% after adjustment and
the result does not approach statistical significance
(P=0.289). The number of smokers (28 premenopausal, 23
postmenopausal) was too small to allow us to examine any
effect of the number ofcigarettes smoked per day.
Table Ill Relationship between SHBG and smoking statusa
Premenopausal Postmenopausal
SHBG SHBG
Smoking
status Unadj.b Adj.c N Unadj.b Adj.d N
Non-smoker 68.6 68.4 152 62.4 62.6 134
Smoker 77.6 78.0 28 67.2 65.9 23
Total 69.9 69.9 180 63.0 63.0 157
aAbbreviations: N=number of subjects; QI =Quetelet's Index;
SHBG=sex hormone binding blobulin; Unadj.=unadjusted. bMean
value (nmoll- 1), corrected for serial number. cAdjusted for QI,
parity (0, 1+), marital status, day of cycle and age at menarche, and
corrected for serial number. dAdjusted for QI, parity (0,1+), marital
status and years since menopause, and corrected for serial number.
Discussion
In this investigation we restricted analysis to premenopausal
or naturally postmenopausal subjects who had no known
history of disease or drug use which would be expected to
influence SHBG. A large number of subjects were excluded
because of current or past use of oral contraceptives or
hormone replacement therapy, both of which have marked
effects on SHBG (Lindstedt et al., 1985).
The mean SHBG concentration was higher in serum
samples which had been stored longer. This was not because
older samples had been thawed and re-frozen more often:
almost all samples were assayed after being thawed for the
first time. This finding agrees with that of Lapidus et al.
(1986) who reported that the mean SHBG concentration
measured by IRMA was about 40% higher in 16 year old
samples than in fresh samples. The reason for this effect is
not known. Any effect of this phenomenon on the
relationship of SHBG to the variables reported here should
be minimal because recruitment date was not significantly
related to any of the variables of interest and because we
used serial number as a covariate in all analyses.
We found no evidence for any diurnal variation in SHBG
in women between 10.00 and 20.00h. This agrees with
Kuoppasalmi (1980) who found no variation in SHBG
binding capacity in male athletes between 10.00 and 17.30h.
Clair et al. (1985) reported a circadian rhythm in SHBG
binding capacity in healthy young men, but the amplitude of
the changes they observed during the day was small.
The inverse relationship between SHBG and various
measures of obesity was first reported in 1970 (de Moor &
Joossens, 1970) and has subsequently been confirmed in
many studies. Our finding of a strong inverse relationship
between SHBG and QI was therefore expected. The absence
of any clear threshold or plateau effects in our data is
consistent with the findings of very high SHBG in anorexics
(Estour et al., 1986) and of very low SHBG in extremely
obese women (Kopelman et al., 1980).
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Maruyama et al. (1984) found an increase in SHBG with
age in women, but they did not consider the effects of
menopausal status or of body weight. We found that SHBG
does not change with age in premenopausal women, but falls
rapidly on cessation of ovarian function at the menopause,
and then gradually rises again during the postmenopause.
The increase in SHBG with years after the menopause is not
understood. In men there is an increase in SHBG after the
age of 50, which is associated with a decrease in total
testosterone (Anderson, 1974). The late postmenopausal
increase in SHBG in women which we have observed could
be associated with an increase in E2, which has been
reported by Chakravarti et al. (1976).
We found that parous premenopausal women had a 12%
higher mean SHBG than nulliparous premenopausal women.
There was no such difference in postmenopausal women.
Bernstein et al. (1985) reported a 10% higher mean SHBG
binding capacity in parous young women than in their
nulliparous sisters. These authors (Bernstein et al., 1986) also
reported that the mean SHBG binding capacity was 10%
higher in women in the early part of their second pregnancy
than in the same women when in the early part of their first
pregnancy. Neither of these findings was statistically
significant.
In our data the lower SHBG of nulliparous premeno-
pausal women is due solely to the lower SHBG of the
unmarried nulliparous women. We found a similar pattern in
postmenopausal women: single nulliparous postmenopausal
women have a lower SHBG than married nulliparous
postmenopausal women. It is possible that SHBG is
unrelated to parity, but that the subset of nulliparous women
who are single are characterized by a lower than average
SHBG. More data are required to resolve this issue.
The unadjusted values for SHBG show a marked increase
with increasing age at menarche in premenopausal women,
and a weak trend in the same direction in postmenopausal
women. Adjusting these values for QI reduces the magnitude
of the relationships. This is because there is a negative
correlation between age at menarche and QI in both
premenopausal and postmenopausal women. The existence
of this relationship, which has been reported before (Gain et
al., 1986), provides additional evidence that there may be
long term physiological characteristics which are correlated
with age at menarche.
Our study suggests that in older premenopausal women
(age 34+), SHBG is positively related to age at menarche.
In the study by Apter et al. (1984) of factors affecting
SHBG, the average SHBG concentration at 10.0 to 15.9
years of age was lower in girls with menarche before 13 than
in girls with a later menarche, and the early pubertal
decrease in SHBG (see Lindstedt et al., 1985) began sooner
in girls with relatively early menarche. However, by 16 years
of age the difference in SHBG was only 4%. The results of
Apter et al. were not adjusted for weight, and the
comparable figure from our data for premenopausal women
(median age 41) is 9% for unadjusted values, and 6% after
adjusting for QI, parity (0, 1+), marital status and day of
cycle.
MacMahon et al. (1982) reported another possible long
term difference between women with early or late menarche.
They found a significant inverse correlation between age at
menarche and urinary oestrogens in women aged 15-19
years. Women aged 30-39 showed a similar but weaker and
non-significant correlation. The authors interpreted their
results as suggesting that women aged 30-39 who had early
menarche still tend to have high oestrogen production, at
least in the follicular phase. Our results suggest that, in
addition, women who underwent early menarche may have
more bioavailable E2 because of the lower SHBG
concentrations.
Two recent studies (Dowsett et al., 1985; Plymate et al.,
1985) reported increases in SHBG in the luteal phase of the
cycle of 15% and 20% respectively. We found that SHBG
was about 9% higher in the first 12 days of the luteal phase
than in the follicular phase, but then dropped by about 14%
in the last 2 days of the cycle. These results appear to be
compatible with those of Dowsett et al. and Plymate et al.:
the smaller luteal phase increase found in our study is
probably explained by the additional variation due to our
study being cross-sectional rather than longitudinal and due
to our assumption of a constant 14 day luteal phase in
contrast to the biochemical detection of ovulation used in
the other studies.
Our observations on the relationship between SHBG and
cigarette smoking must be treated cautiously because of the
small number of smokers on which they are based. In
postmenopausal women we found that SHBG was 5% higher
in smokers than in non-smokers, but this was not
statistically significant, in agreement with the results of
Lapidus et al. (1986). In premenopausal women we found
that SHBG was 13% higher in smokers than in non-
smokers. We have been unable to find another report of
SHBG and smoking in premenopausal women. We did not
use smoking category as a covariate in analysis of other
variables because we only had data on smoking for 28% of
the subjects; repeating the analyses in the subset of subjects
for whom smoking data were available did not suggest that
smoking confounded the other relationships described. We
are currently gathering more data on smoking in this
population.
We have observed the well established relationship
between SHBG and QI and found a correlation between
SHBG and age at menarche in premenopausal women. The
relationship between parity and SHBG is still unclear.
Obesity (in postmenopausal women), early age at menarche,
and nulliparity are all risk factors for breast cancer (Pike &
Ross, 1984). These factors may affect risk partly through
their association with SHBG.
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